By identifying these novel tumor MHC-bound peptides from sequences usually not included in MHC-bound peptide discovery pipelines, either from cancer-specific ncORFs or from somatic mutations, we contributed to increasing the current knowledge of the true richness of the cancer immune repertoire. This evidence concerns the gene HLA-C and cancer.